CompletedPhase 3

Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer

Italy180 participantsStarted 2003-12

Plain-language summary

The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.

Who can participate

Age range18 Years – 75 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed prostate cancer * Locally advanced prostate cancer patients suitable for Casodex 150 mg monotherapy Exclusion Criteria: * Age \> 75 yrs * No metastatic disease (M1). * No presence of gynaecomastia and/or mastalgia at screening * No therapy with medications able to provoke gynaecomastia and/or mastalgia within 6 months of trial entry.

What they're measuring

Incidence of Gynecomastia and Breast pain at 2, 6 months and every 6 months thereafter and/or at withdrawal visit.

Trial details

NCT IDNCT00233610

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-10

View on ClinicalTrials.gov More Prostate Cancer trials